SEC Form 4 · accession 0001209191-18-027108
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martijn Kleijwegt
Director
Period of report
Apr 30, 2018
Accepted (ET)
May 1, 2018 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Apr 30, 2018 | P | 300,000 | $9.75 | A | 2,953,673 | I | By LSP investment fund |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018.
- F2Represents shares of the Issuer held by LSP V Cooperatieve U.A. ("LSP V"). LSP V Management B.V. ("LSP V Management") is the director and manager of LSP V. Mr. Kleijwegt is a Managing Director of LSP V Management. By virtue of this relationship, Mr. Kleijwegt may be deemed to share voting and dispositive power with respect to the shares held by LSP V. Mr. Kleijwegt disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.